Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer

Impact · against what's priced in

Genmab's positive Phase 2 data for petosemtamab provides a significant catalyst for its mCRC pipeline. The high objective response rates in first- and second-line settings increase the probability of success for ongoing Phase 3 trials and potentially raise peak sales estimates.

GMAB+0.70: No priced-in read yet

Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer

What matters in this story

Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer

What matters in this story

Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

How each ticker is affected

Track these names every morning.

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026

Adagene Eyes Phase II Data for Masked CTLA-4 Therapy in MSS Colorectal Cancer

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer

What matters in this story

Next reads from the same story arc

Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer

What matters in this story

Next reads from the same story arc

Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

How each ticker is affected

Track these names every morning.

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026

Adagene Eyes Phase II Data for Masked CTLA-4 Therapy in MSS Colorectal Cancer

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting